Hikma Pharmaceuticals Plc Blocklisting Application (5024B)
08 Ottobre 2020 - 09:38AM
UK Regulatory
TIDMHIK
RNS Number : 5024B
Hikma Pharmaceuticals Plc
08 October 2020
Block Listing of Shares
Hikma Pharmaceuticals PLC
LONDON, 8 October 2020- The Board of Hikma Pharmaceuticals PLC
("Hikma") (LSE: HIK) (LEI: 549300BNS685UXH4JI75) (NASDAQ: HIK),
announces that it has made a block listing application to the
Financial Conduct Authority and the London Stock Exchange plc for a
total of 1,000,000 ordinary shares of 10p each in the capital of
the Company to be admitted to the Official List of the UK Listing
Authority. It is expected that admission will be granted on 9
October 2020.
The shares, when issued, will be issued fully paid and rank pari
passu in all respects with the existing issued ordinary shares of
the Company. The shares will be issued pursuant to the vesting of
shares under the Hikma Pharmaceuticals PLC the 2014 Executive
Incentive Plan (the "Plan"). Participants in the Plan have or will
become entitled to these shares following the vesting of the
shares.
- ENDS -
Enquiries
Hikma Pharmaceuticals PLC
Peter Speirs
Company Secretary +44 20 7399 2760
About Hikma
Hikma helps put better health within reach every day for
millions of people in more than 50 countries around the world. For
more than 40 years, we've been creating high-quality medicines and
making them accessible to the people who need them. Headquartered
in the UK, we are a global company with a local presence across the
United States (US), the Middle East and North Africa (MENA) and
Europe, and we use our unique insight and expertise to transform
cutting-edge science into innovative solutions that transform
people's lives. We're committed to our customers, and the people
they care for, and by thinking creatively and acting practically,
we provide them with a broad range of branded and non-branded
generic medicines. Together, our 8,600 colleagues are helping to
shape a healthier world that enriches all our communities. We are a
leading licensing partner, and through our venture capital arm, are
helping bring innovative health technologies to people around the
world. For more information, please visit: www.hikma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ALSFIFVDISLTIII
(END) Dow Jones Newswires
October 08, 2020 03:38 ET (07:38 GMT)
Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Storico
Da Mar 2023 a Mar 2024